Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Tengion, Inc. (Nasdaq: TNGN) settles for the bounce

|Includes: Tengion, Inc. (TNGNQ)

Tengion, Inc. (Nasdaq: TNGN), US clinical-stage biotechnology company, said it had discussed a possible stock-for-stock tie-up with a listed company, but the recent rise in its trading share price had pushed the interested party away.

Tengion’s stock back down from $5.50s to $2.80s & settles for the bounce

Tengion Addresses Recent Trading Activity in its Common Stock

PR Newswire   ”Press Releases US – English”
EAST NORRITON, Pa. , Feb. 16, 2011 /PRNewswire/ — Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that it has been engaged in negotiations with a publicly traded company relating to the acquisition of Tengion through a stock-for-stock merger. As a result of the recent increases in the trading price and volume of Tengion ‘s common stock, Tengion ‘s potential acquirer has terminated merger negotiations.

As has previously been stated in the Company’s filings with the Securities and Exchange Commission , Tengion believes it has sufficient cash to fund its operations into April 2011 . If Tengion cannot secure either a sale transaction or alternative financing through partnership or equity investment, Tengion may need to take steps to wind down its operations so as to preserve the value of its assets for the benefit of its creditors and stockholders.